Contract research organization NAMSA today announced its acquisition of Minneapolis-based American Preclinical Services (APS). This purchase follows NAMSA’s acquisition of New York-based Syntactx, a clinical research services CRO, in January.
The acquisition will provide NAMSA customers with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs, imaging capabilities and surgical suites, according to NAMSA. These services, delivered within APS’s 130,000 ft2 facility, will enable medtech developers to perform safety and performance evaluations for early-stage R&D efforts, as well as integrated preclinical-to-clinical work for complex medical device programs.
“APS is excited to join forces with NAMSA, the pioneer and long-standing leader of the medical device testing industry,” said APS president & CEO Michael Conforti in a news release.
“NAMSA is extremely pleased to add to its global portfolio of preclinical development solutions through the acquisition of APS,” added John Gorski, president & CEO of NAMSA. “We are excited to enhance the NAMSA client experience and also offer APS clients further efficiencies throughout the full development continuum.”
The acquisition of APS’s Minneapolis preclinical laboratory brings NAMSA to 13 locations throughout APAC, Europe and North America.
The price and terms of the transaction were not disclosed.
